Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east Asian Patients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study

Yong Wang, Hong-wei Zhao, Cheng-fu Wang, Xiao-jiao Zhang, Jie Tao, Chun-sheng Cui, Qing-kun Meng, Yu Zhu, De-feng Luo, Ai-jie Hou * and Bo Luan *

Abstract

Background: Patients with coronary chronic total occlusion (CTO) require effective antiplatelet therapy after percutaneous coronary intervention (PCI). Ticagrelor has more pronounced platelet inhibition than clopidogrel. However, the most appropriate dose of ticagrelor in East Asian populations remains unclear.

Method: We compared ticagrelor (180 mg loading dose, 90 mg twice daily thereafter and 120 mg loading dose, 60 mg twice daily thereafter) and clopidogrel (300 mg loading dose, 75 mg daily thereafter) for prevention of cardiovascular events in 525 patients with CTO undergoing PCI.

Results: The rate of in-hospital major adverse cardiac and cerebral events (MACCE) was not different between the groups. At 1-year follow-up, target vessel revascularization (TVR) in both ticagrelor groups were significantly lower than that in the clopidogrel group ($p = 0.047$); TVR was significantly decreased in 60 mg ticagrelor compared to standard dose clopidogrel ($p = 0.046$). At 1-year follow-up, overall MACCE in both ticagrelor groups were significantly lower than that in the clopidogrel group ($p = 0.023$). Kaplan–Meier analysis showed MACCE-free survival was significantly higher in both ticagrelor groups than in the clopidogrel group ($p = 0.024$). During hospitalization, minor bleeding was significant increased in the 90 mg ticagrelor group ($p = 0.021$). At 1-year follow-up, risk of major and minor bleeding were significantly increased in the 90 mg ticagrelor group.

Conclusion: In East Asian patients with CTO undergoing PCI, 60 mg ticagrelor was as effective as 90 mg, at the same time significantly reduced risk of bleeding.

Keywords: Ticagrelor, Clopidogrel, Chronic total occlusion, Percutaneous coronary intervention
Introduction
CTO was defined as thrombolysis in myocardial infarction (TIMI) grade-0 flow with a duration of 3 months, documented angiographically or clinically defined [1]. From previous studies, approximately 20% of patients with coronary heart disease have at least one CTO lesion [1]. Accumulating evidence has confirmed that successful revascularization can effectively improve myocardial ischemia, relieve angina [2], improve left ventricular function [3], and improve clinical outcomes [4, 5] in CTO patients. However, a higher risk of CTO-PCI, a longer duration of the procedure, and a larger number of implanted stents required more intensive anticoagulation during the perioperative period. Ticagrelor is a reversible antagonist of the P2Y12 receptor with a more rapid onset and more pronounced platelet inhibition, it is widely used in dual antiplatelet therapy following PCI. Studies have shown that ticagrelor can significantly reduce the rate of the composite endpoints of cardiovascular death, myocardial infarction, and stroke compared to clopidogrel, and does not cause an increase in major bleeding events [6]. However, most of the patients included in these clinical studies were from European and American Caucasian populations. Currently, an increasing number of studies have confirmed that the risk of thrombosis and hemorrhagic disease in East Asian populations is different from those in Caucasian populations [7, 8]. Therefore, it is important to investigate suitable doses of ticagrelor in East Asian populations.

This study sought to investigate whether low-dose ticagrelor (120 mg loading dose, 60 mg twice daily thereafter) could reduce risk of bleeding events in CTO patients following PCI, meanwhile whether the ischemic events could be increased compared to compared to standard dose of ticagrelor and 75 mg clopidogrel, thereby providing a reference for clinical decision making.

Method
Study design and patients
In this study, patients with a confirmed diagnosis of CTO undergoing successfully PCI were retrospective selected from January 2015 to May 2018 in our hospital. Exclusion criteria: pregnant women, patients allergic to aspirin, clopidogrel, or ticagrelor; refusal of PCI or failure of stents implantation, patients with an indication of anticoagulants, patients with comorbidities (including coronary artery perforation, intramural hematomas and any comorbidities that may result in a worse prognosis), life expectancy less than 1 year, refusal to participate in the trial. A total of 541 patients were enrolled in the study, of which 16 were lost to follow-up, and eventually 525 CTO patients who successfully underwent PCI were included in the study. Of these patients, 171 received a loading dose of 180 mg ticagrelor followed by a maintenance dose of 90 mg twice daily, 178 received a loading dose of 120 mg ticagrelor followed by a maintenance dose of 60 mg twice daily, and 176 received a loading dose of 300 mg clopidogrel followed by 75 mg daily. All patients received a loading dose of 300 mg aspirin followed by a daily oral dose of 100 mg (Fig. 1).

The routine access of the procedure was radial artery, and the physician determined the access as needed. During the procedure, a standard dose of unfractionated heparin (100 IU/kg) was used for anticoagulant therapy, and 2000 IU of unfractionated heparin was added every hour. The use of glycoprotein IIb/IIIa inhibitor (GPI) was left to the physician’s discretion. The study was approved by the Institutional Review Board of the People’s Hospital of Liaoning Province, and all patients signed informed consent before participation.

Statistical analysis
Statistical Package for Social Sciences (SPSS) for Windows 20 (IBM SPSS Inc., Chicago, IL) was used for statistical analysis. Normally distributed continuous data are presented as mean ± standard deviation, and those not normally distributed are shown as median (min-max). Categorical variables are shown as numbers and percentages. To compare continuous variables, the Student t-test or Mann-Whitney U test were used, and to compare categorical variables, the chi-square test and the Fisher's exact test were used in the case of sparse data. Kaplan-Meier graphs were used to assess survival without MACCE. All tests were two sided, and p values < 0.05 was considered significant.
In this study, 541 patients with CTO-PCI were recruited consecutively from January 2015 to May 2018 at our hospital. All the procedures were performed by one physician (corresponding author: Bo Luan). All the patients received guideline based optimal medical therapy. The follow-up endpoint was May 2019. 16 patients were lost to follow-up, and in the end 525 CTO patients who successfully underwent coronary interventional therapy were included in the study (Fig. 1). The baseline and procedural characteristics were not statistically different among the three groups and the medication used were comparable between the groups (Tables 1 and 2).

### Table 1 Clinical characteristics of study population

| Variables                      | Ticagrelor 90 mg (n = 171) | Ticagrelor 60 mg (n = 178) | Clopidogrel 75 mg (n = 176) | P-value |
|--------------------------------|-----------------------------|-----------------------------|-----------------------------|---------|
| Age (years)                    | 63.5 ± 7.4                  | 65.3 ± 8.2                  | 64.9 ± 7.1                  | 0.469   |
| Gender (female), n(%)          | 62 (36.3%)                  | 68 (38.2%)                  | 67 (40.3%)                  | 0.741   |
| Body mass index (Kg/m²)        | 23.8 ± 3.4                  | 23.5 ± 3.8                  | 24.2 ± 3.9                  | 0.869   |
| Diabetes Mellitus, n(%)        | 52 (30.4%)                  | 58 (32.6%)                  | 56 (31.8%)                  | 0.910   |
| Hypertension, n(%)             | 92 (53.8%)                  | 85 (47.8%)                  | 82 (46.6%)                  | 0.363   |
| Current smoker, n(%)           | 69 (40.4%)                  | 75 (42.1%)                  | 72 (40.9%)                  | 0.937   |
| Previous MI, n(%)              | 82 (48.0%)                  | 80 (44.9%)                  | 78 (44.3%)                  | 0.772   |
| Previous ischemic CVA, n(%)    | 39 (22.8%)                  | 45 (25.3%)                  | 38 (21.6%)                  | 0.710   |
| Previous GI bleeding, n(%)     | 7 (4.1%)                    | 8 (4.5%)                    | 5 (2.8%)                    | 0.716   |
| Peptic Ulcer, n(%)             | 21 (12.3%)                  | 25 (14.0%)                  | 24 (13.6%)                  | 0.886   |
| LVEF(%)                        | 43.2 ± 5.5                  | 44.4 ± 6.7                  | 43.9 ± 5.8                  | 0.863   |
| NYHA 2–3 on admission, n(%)    | 115 (67.3%)                 | 109 (61.2%)                 | 112 (63.6%)                 | 0.499   |
| eGFR, ml/min/1.73 mm²          | 64.5 ± 21.7                 | 65.1 ± 21.9                 | 63.9 ± 22.4                 | 0.782   |
| CRUSADE score                  | 32.1 ± 5.2                  | 33.4 ± 5.5                  | 32.8 ± 6.2                  | 0.792   |
| Medication                     |                             |                             |                             |         |
| ACEI/ARB, n(%)                 | 80 (46.8%)                  | 75 (42.1%)                  | 82 (46.6%)                  | 0.622   |
| Beta-blockers, n(%)            | 75 (43.9%)                  | 69 (38.8%)                  | 78 (44.3%)                  | 0.515   |
| Statin, n(%)                   | 165 (96.5%)                 | 170 (95.5%)                 | 166 (94.3%)                 | 0.634   |
| PPI, n(%)                      | 166 (97.1%)                 | 174 (97.8%)                 | 170 (96.6%)                 | 0.807   |

**Abbreviations:** MI, myocardial infarction; CVA, cerebrovascular accident; GI, gastrointestinal; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; PPI, proton pump inhibitor
Efficacy endpoint events

There was no difference in the rate of in-hospital major adverse cardiac and cerebral events (MACCE) between the studied groups. However, at 1-year follow-up, target vessel revascularization (TVR) in the two ticagrelor dose groups were significantly lower than that in the clopidogrel group (2.8% vs. 2.3% vs. 7.4%, \( p = 0.047 \)). TVR in 60 mg ticagrelor group was similar with 90 mg groups (2.3% vs. 2.8%, \( p = 1.00 \)) and was significantly lower compared to the standard dose of clopidogrel (2.8% vs. 7.4%, \( p = 0.046 \)). At 1-year follow-up, the overall MACCE of the two ticagrelor dose groups were significantly lower than that of the clopidogrel group (7.3% vs. 6.4% vs. 14.2%, \( p = 0.023 \)). MACCE in 60 mg ticagrelor group was

### Table 2 Procedure-related characteristics of the studied patients

| Variables                  | Ticagrelor 90 mg (n = 171) | Ticagrelor 60 mg (n = 178) | Clopidogrel 75 mg (n = 176) | P-value |
|----------------------------|----------------------------|----------------------------|-----------------------------|---------|
| Site of access             |                            |                            |                             |         |
| Radial                     | 58 (33.9%)                 | 52 (29.2%)                 | 54 (30.7%)                  | 0.627   |
| Femoral                    | 23 (13.5%)                 | 41 (23.0%)                 | 35 (19.9%)                  | 0.067   |
| Radial and Femoral         | 90 (52.6%)                 | 85 (47.8%)                 | 87 (49.4%)                  | 0.657   |
| Total amount of contrast (ml)| 233.8 ± 102.0               | 228.3 ± 98.6               | 215.8 ± 94.6                | 0.327   |
| Total time of procedure (min)| 123.6 ± 55.9                | 119.8 ± 57.5               | 128.4 ± 64.3                | 0.621   |
| LAD occlusion, n (%)       | 60 (35.1%)                 | 55 (30.9%)                 | 58 (33.0%)                  | 0.716   |
| LCX occlusion, n (%)       | 32 (18.7%)                 | 29 (16.3%)                 | 28 (15.9%)                  | 0.766   |
| RCA occlusion, n (%)       | 89 (52.0%)                 | 96 (53.9%)                 | 92 (52.3%)                  | 0.939   |
| Occlusion lesion length, mm| 58.4 ± 26.3                 | 55.9 ± 24.6                | 56.6 ± 25.4                 | 0.748   |
| Retrograde filling > grade 2| 85 (49.7%)                 | 82 (46.1%)                 | 81 (46.0%)                  | 0.730   |
| Reverse wire technique     | 44 (25.7%)                 | 51 (28.7%)                 | 48 (27.3%)                  | 0.827   |
| IABP, n(%)                 | 12 (7.0%)                  | 9 (5.1%)                   | 11 (6.3%)                   | 0.743   |
| IVUS, n(%)                 | 34 (19.9%)                 | 38 (21.3%)                 | 36 (20.5%)                  | 0.953   |
| Number of stents per patient| 2.8 ± 1.9                  | 2.6 ± 1.8                  | 2.7 ± 2.0                   | 0.568   |
| Stent length (mean, mm)    | 65.9 ± 26.3                 | 66.4 ± 29.5                | 67.2 ± 31.4                 | 0.382   |
| TIMI III flow after PCI    | 152 (88.9%)                | 162 (91.0%)                | 158 (89.8%)                 | 0.814   |
| Glycoprotein IIb/IIIa receptor inhibitor, n(%) | 46 (26.9%)                | 55 (30.9%)                | 52 (29.5%)                  | 0.716   |
| LMWH, (%)                  | 50 (29.2%)                 | 48 (27.0%)                 | 56 (31.8%)                  | 0.611   |

Abbreviations: LAD Left anterior descending artery, LCX Left circumflex coronary artery, RCA Right coronary artery IABP, Intra-aortic balloon pump, IVUS Intravascular ultrasonography, TIMI Thrombolysis in myocardial infarction, LMWH Low-molecular-weight heparin

### Table 3 MACCE of In-Hospital and 12-Months Follow-Up

| Variables                  | Ticagrelor 90 mg (n = 171) | Ticagrelor 60 mg (n = 178) | Clopidogrel 75 mg (n = 176) | P-value |
|----------------------------|----------------------------|----------------------------|-----------------------------|---------|
| All-cause mortality, n(%)  | 1 (0.6%)                   | 1 (0.6%)                   | 2 (1.1%)                    | 0.848   |
| MI, n(%)                   | 2 (1.2%)                   | 1 (0.6%)                   | 2 (1.1%)                    | 0.749   |
| Stent thrombosis, n(%)     | 1 (0.6%)                   | 2 (1.1%)                   | 4 (2.3%)                    | 0.465   |
| Stroke, n(%)               | 1 (0.6%)                   | 1 (0.6%)                   | 1 (0.6%)                    | 1       |
| TVR, n(%)                  | 3 (1.8%)                   | 2 (1.1%)                   | 7 (4.0%)                    | 0.213   |
| Overall MACCE, n(%)        | 5 (2.9%)                   | 5 (2.8%)                   | 9 (5.1%)                    | 0.454   |

| Variables                  | Ticagrelor 90 mg (n = 171) | Ticagrelor 60 mg (n = 178) | Clopidogrel 75 mg (n = 176) | P-value |
|----------------------------|----------------------------|----------------------------|-----------------------------|---------|
| All-cause mortality, n(%)  | 2 (1.2%)                   | 1 (0.6%)                   | 2 (1.1%)                    | 0.749   |
| MI, n(%)                   | 2 (1.2%)                   | 3 (1.7%)                   | 5 (2.8%)                    | 0.576   |
| Stent thrombosis, n(%)     | 4 (2.3%)                   | 4 (2.2%)                   | 6 (3.4%)                    | 0.792   |
| Stroke, n(%)               | 1 (0.6%)                   | 0                         | 1 (0.6%)                    | 0.551   |
| TVR, n(%)                  | 4 (2.3%)                   | 5 (2.8%)                   | 13 (7.4%)                   | 0.047   |
| Overall MACCE, n(%)        | 11 (6.4%)                  | 13 (7.3%)                  | 25 (14.2%)                  | 0.023   |

Abbreviations: MACCE Major adverse cardiac and cerebral events, TVR Target vessel revascularization, MI Myocardial infarction
similar with 90 mg ticagrelor groups (7.3% vs. 6.4%, \( p = 0.748 \)) and was significantly decreased compared to the standard dose of clopidogrel (7.3% vs. 14.2%, \( p = 0.036 \)) (Table 3). Kaplan–Meier analysis showed that MACCE-free survival was significantly higher in ticagrelor groups than in the 75 mg clopidogrel group (\( p = 0.024 \)), MACCE-free survival was significantly higher in the 90 mg ticagrelor group compared to the clopidogrel group (\( p = 0.020 \)), MACCE-free survival was significantly higher in the 60 mg ticagrelor group compared to the clopidogrel group (\( p = 0.037 \)), and there was no significant difference between the 60 mg and 90 mg ticagrelor groups (\( p = 0.762 \)) (Fig. 2).

**Safety endpoint events**
During hospitalization, there was a significant increase in the risk of minor bleeding in the 90 mg ticagrelor group (18.1% vs. 10.1% vs. 9.1%, \( p = 0.021 \)), although no increased risk of major bleeding was observed. The risk of minor bleeding in the 60 mg ticagrelor group was significantly lower than in the 90 mg ticagrelor group (10.1% vs. 18.1%, \( p = 0.044 \)) and similar to that of the clopidogrel group (10.1% vs. 9.1%, \( p = 0.857 \)). At the 1-year follow-up, the risk of major bleeding (4.1% vs. 0.6% vs. 0.6%, \( p = 0.016 \)) and minor bleeding (23.4% vs. 12.4% vs. 11.9%, \( p = 0.004 \)) were significantly higher in the 90 mg ticagrelor group. The risk of major bleeding (0.6% vs. 4.1%, \( p = 0.034 \)) and minor bleeding (12.4% vs. 23.4%, \( p = 0.007 \)) were significantly lower in the 60 mg ticagrelor group than in the 90 mg ticagrelor group. There was no significant difference in the risk of major bleeding (0.6% vs. 0.6%, \( p = 1.000 \)) or minor bleeding (12.4% vs. 11.9%, \( p = 1.000 \)) between the 60 mg ticagrelor group and the clopidogrel group (Table 4).

**Discussion**
This is the first study to investigate the efficacy and safety of a low-dose ticagrelor (60 mg twice daily) antiplatelet regimen in East Asian patients with CTO undergoing PCI. We found that low-dose ticagrelor achieved similar effect in reducing the risk of revascularization and overall MACCE compared to 90 mg group with a significant lower risk of major and minor bleeding events.

A higher risk of CTO-PCI, a longer duration of the procedure, and a larger number of implanted stents required more intensive anticoagulation during the perioperative period. However, the optimal antiplatelet therapy after CTO-PCI is still unclear. In 2014 we found that 90 mg ticagrelor for CTO-PCI resulted in a significant bleeding events in asian patients and 75 mg clopidogrel resulted in a significant ischemic events, at that time, we assumed that a low dose ticagrelor may be an alternative. So we start our study in 2015. Ticagrelor 60
mg tablet was on market in China since March 2018. Before that, we use 2/3 of 90 mg, after March 2018, 60 mg is available. In this study, we retrospectively analyse a low dose of ticagrelor (120 mg loading dose, 60 mg twice daily thereafter) for prevention of cardiovascular events in 525 patients with CTO undergoing PCI.

A growing body of evidence has shown that ticagrelor can significantly reduce the rate of the composite end points of cardiovascular death, myocardial infarction, and stroke compared to clopidogrel, and does not cause an increase in major bleeding events [6]. However, most of the patients included in these clinical studies were from European and American Caucasian populations. Currently, an increasing number of studies have confirmed that the risk of thrombosis and hemorrhagic disease in East Asian populations is different from those in Caucasian populations [7, 8]. During antithrombotic treatment, East Asian patients tended to have a lower risk of ischemic events especially in coronary artery disease and a higher incidence of bleeding [7, 8]. Some researchers suggested that East Asian patients have a lower risk of ischemic events after PCI despite a lower response to clopidogrel [11–13]. In addition, studies have shown that East Asian populations have significantly increased risk of gastrointestinal bleeding even with low-intensity antiplatelet therapy (such as low-dose aspirin) compared to Caucasians [14]. Therefore, it is important to investigate suitable doses of ticagrelor in East Asian populations.

The GEMINI-ACS-1 randomized study confirmed that Asia Pacific patients with acute coronary syndrome had significantly more clinically significant bleeding events during antithrombotic therapy compared to other regions [15]. A study from South Korea showed that patients prescribed 90 mg ticagrelor had a 40.6% risk of bleeding in one month follow up [16]. Studies have confirmed that the presence of ticagrelor and its major active metabolite (ARC124910XX) is significantly higher in East Asian population than in the Caucasian population [17, 18]. Therefore, a low dose of ticagrelor in the East Asian population can achieve a similar rate of platelet inhibition while reducing the risks of bleeding. In the sub-study of the PEGASUS-TIMI 54 study, post-dose plasma level of ticagrelor was 38% lower with 60 mg than with 90 mg, but levels of platelet reactivity in both doses did not differ [19]. Similarly, low-dose ticagrelor (60 mg twice daily) and standard-dose ticagrelor (90 mg twice daily) exhibited similar 30-day rates of platelet inhibition in East Asian ACS patients [20].

A crossover study including Chinese patients with stable coronary artery disease evaluated the antiplatelet effect of very low-dose of ticagrelor (22.5 mg twice daily) vs. standard-dose of clopidogrel (75 mg daily) for 7 days. They found that the level of platelet reactivity in the ticagrelor group was significantly lower than that in the clopidogrel group [21]. Thus, we have reason to believe that low doses of ticagrelor are more suitable for the Asian population. We sought to investigate the efficacy and safety of low-dose (60 mg) ticagrelor in antiplatelet therapy of CTO patients following PCI. Similar to previous studies, low-dose ticagrelor could significantly reduce composite MACCE compared to standard dose of clopidogrel. In addition, the associated risks of bleeding, including major and minor bleeding, were significantly reduced compared to the 90 mg dose. To some extent, this indicates that low doses of ticagrelor are effective and safe in the Asian population.

In clinical practice, it is of vital importance to assess the ischemic and bleeding risk for the individual, since antiplatelet therapy plays pivotal role in patients with CTO-PCI. The GRACE and CRUSADE score are widely recommended for the ischemic events and bleeding risk classification, respectively. For patients at high risk of bleeding, we speculate that low-dose ticagrelor is superior to standard-dose clopidogrel. In this study, subgroup analysis was not performed due to sample size limitations, which may lead to some bias in the results.

Although this study investigated the efficacy and safety of low-dose ticagrelor antiplatelet therapy following successful PCI in East Asian CTO patients, the following limitations exist: (1) The present study did not conduct measurements of cytochrome P450 2C19 gene, which is critical for clopidogrel metabolism; (2) The present study is a single-center retrospective analysis with a small sample size, which may lead to research bias, (3) Because of the small sample size, no subgroup analysis was performed. Thus, a large-sample, multi-center, prospective

| Variables                              | Ticagrelor 90 mg (n = 171) | Ticagrelor 60 mg (n = 178) | Clopidogrel 75 mg (n = 176) | P-value |
|----------------------------------------|-----------------------------|-----------------------------|-----------------------------|---------|
| Bleedings in hospital                  |                             |                             |                             |         |
| Major bleeding, n(%)                   | 2 (1.2%)                    | 1 (0.6%)                    | 1 (0.6%)                    | 0.699   |
| Minor bleeding, n(%)                   | 31 (18.1%)                  | 18 (10.1%)                  | 16 (9.1%)                   |         |
| Bleedings during 12-month follow-up    |                             |                             |                             |         |
| Major bleeding, n(%)                   | 7 (4.1%)                    | 1 (0.6%)                    | 1 (0.6%)                    | 0.016   |
| Minor bleeding, n(%)                   | 40 (23.4)                   | 22 (12.4%)                  | 21 (11.9%)                  | 0.004   |
randomized controlled trial is needed in the future to validate our conclusions.

**Conclusion**
In conclusion, our data suggest that In East Asian patients with CTO undergoing PCI, 60 mg ticagrelor was as effective as 90 mg, at the same time significantly reduced risk of bleeding.

**Abbreviations**
CTO: Coronary chronic total occlusion; GPI: Glycoprotein IIb/IIIa inhibitor; MACCE: Major adverse cardiac and cerebral events; PCI: Percutaneous coronary intervention; TIMI: Thrombolysis in myocardial infarction; TVR: Target vessel revascularization

**Acknowledgements**
Not Applicable.

**Authors’ contributions**
Dr. YW, HWZ and Professor AJH acquired the data, performed statistical analyses, and drafted the manuscript. Professor BL, Dr. CFW, XJZ, and JT conceived the study, participated in its design and coordination, helped to draft the manuscript, and revised the manuscript critically for important intellectual content. Dr. CSC, Dr. QMK, Dr. YZ and DFL revised the manuscript critically for important intellectual content. All authors contributed to the study design and data interpretation, and all authors read and approved the final manuscript.

**Funding**
None.

**Availability of data and materials**
The datasets generated and analysed during the current study are not publicly available due to a further study of this area but are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**
The study had already been approved by Ethics Committee of the People’s Hospital of China Medical University and all subjects provided their informed, written consent before participation.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

Received: 2 October 2019 Accepted: 11 December 2019

**References**
1. Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz RS, Bailey S, Moussa I, Teirstein PS, Dangas G, Bain DS, Selmon M, Strauss BH, Tanami H, Suzuki T, Mitsudo K, Kato H, Cox DA, Hoye A, Mintz GS, Grube E, Cannon LA, Reifart NJ, Reisman M, Abizaid A, Moses JW, Leon MB, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circ. 2005;112(15):2364–72.
2. Rossello X, Pujadas S, Serra A, Bajo E, Carrares F, Barros A, Cinca J, Pons-Lladó G, Vaquerizo B. Assessment of inducible myocardial ischemia, quality of life, and functional status after successful percutaneous revascularization in patients with chronic Total coronary occlusion. Am J Cardiol. 2016;117(5):260–6.
3. Hoebers LP, Claessen BE, Elias J, Dangas GD, Mehran R, Henriques JP. Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. Int J Cardiol. 2015;187:90–6.
4. Tomasello SD, Boukhris M, Giubilotto S, Marzà F, Garbo R, Contegiacomo G, Marzocchi A, Niccoli G, Gagnon A, Varbelia F, Desidera A, Rubartelli P, Cioppa A, Baralis G, Galassi AR. Management strategies in patients affected by chronic total occlusions: results from the Italian registry of chronic Total occlusions. Eur Heart J. 2015;36(45):3189–98.
5. Hoye A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total occlusions: theThoraxcenter experience 1992-2002. Eur Heart J. 2005;26(24):2630–6.
6. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horow J, Husted S, James S, Katus H, Majaffrey KW, Scirica BM, Skene A, Steg PG, Storey RF, Hassington RA; PLATO investigators. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes, N. Engl. J. Med. 2009;361(11):1045–57.
7. Levine, Jeong GN, Goto Y-H, Anderson S, Hlu H, Yang Y, Taubert JL, Smith K, Sidney C. Expert consensus document: World Heart Federation expert consensus statement on antplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat. Rev. Cardiol. 2014;11:597–606.
8. Jeong YH. “East Asian paradox”: challenge for the current antplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Curr. Cardiol. Rep. 2014;16:458.
9. Thaygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Rakvilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Baix J, Beller GA, Boronow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández-Avilés F, Fox KM, Parkhomenko AN, Prior SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemsan I, Krithsden SD, McGregor K, Sechtem U, Silber S, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrov D, Lim M, Martinez-Rico MA, Steinhibl S, Levine GN, Glibler WB, Goff D, Tubaro M, Dudek D, Al-Atrar N. Universal definition of myocardial infarction. Circ. 2007;116:2634–53.
10. Choi JJ, Seo JM, Lee DH, Park K, Kim YD. Clinical utility of new bleeding criteria: a prospective study of evaluation for the bleeding academic research consortium definition of bleeding in patients undergoing percutaneous coronary intervention. J. Cardiovasc. Interv. 2015;89(9):825–45.
11. Daemen J, Wenaaweser P, Tscheschka K, Abrecht L, Vaina S, Morger C, Kukjes N, Jun J, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667–78.
12. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasuoto H, Nishikawa H, Hisa Y, Maramatu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobeuoshi M, Kita T, Mitsudo K; j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circ. 2009;119(7):987–95.
13. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc. Interv. 2010;3(5):494–503.
14. Ma C. Current antithrombotic treatment in East Asia: some perspectives on one-guideline-fits-all races in acute coronary syndrome. Curr. Cardiol. Rep. 2012;14(10):1014–8.
15. Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mund H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissoni D, Bueno H, Clevyus MJ, Nicola JC, Connel JH, Goto S, Kiss RG, Guray U, Park DW, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799–808.
16. Kang MK, Kim K, Ba EJ, Ahn JH, Jang JY, Park HW, Koh JS, Park Y, Hwang S-J, Kwak CH, Hwang J-Y, Jeong YH. Bleeding episode predicts the occurrence of dyspnea during ticagrelor treatment in patients with acute coronary syndrome. Circ. 2017;136A:20526.
17. Liu H, Butler K, Yang L, Yang Z, Teng R. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-Centre study. Cln Drug Investig. 2012;32(2):87–97.
18. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. Int J Clin Pharmacol Ther. 2014;52(6):478–91.
19. Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Braunwald E, Sabatine MS. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol. 2016;67(10):1145–54.
20. Park DW, Lee PH, Jang S, Lim HS, Kang DY, Lee CH, Ahn JM, Yun SC, Park SW, Park SJ. Effect of low-dose versus standard-dose ticagrelor and clopidogrel on platelet inhibition in acute coronary syndromes. J Am Coll Cardiol. 2018;71(14):1594–5.

21. He M, Liu B, Sun D, Pan Y, Zheng W, Shi J, Zhao S, Dong X, Lu S, Li M, Han Y, Li Y. One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: a randomized, single-blind, crossover clinical study. Int J Cardiol. 2016;215:209–13.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.